DraftUnitedHealthcarePolicy CS016NM.B

Chelation Therapy (for New Mexico Only)

Policy governing medical necessity and coverage of chelation therapy for diagnosis and treatment of heavy metal toxicity and overload conditions, and exclusion of chelation for specified non‑overload uses in New Mexico.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy (for New Mexico Only)

Policy CodePolicy CS016NM.B

Change TypeTitle and clinical clarification (material)

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain and include validated laboratory testing demonstrating metal intoxication (e.g., blood lead level) in documentation to support authorization for chelation.

SourceLink

POLICY UPDATE CHANGES

Title changed from 'Chelation Therapy for Non-Overload Conditions (for New Mexico Only)' to 'Chelation Therapy (for New Mexico Only)'.

Policy language clarified to state chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary.

Clinical Evidence and References sections were updated to reflect current information.

New MexicoJurisdiction

Heavy metal overloadCovered for

Non‑overload usesNot supported for

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Multiple J/HCPCSCodes listed

CS016NM.A archivedPrevious version

Coverage Criteria

Medical necessity for chelation in overload conditions

Covered when ALL of the following are met:

Confirmed metal overload: There is a documented diagnosis of heavy metal toxicity or overload (for example, iron, copper, lead, aluminum) established using validated laboratory testing and appropriate reference values.

Diagnostic workup must consider history, appropriate testing methods, and accurate reference values.

Indication supported by evidence or guideline: The indication for chelation is consistent with evidence and guideline recommendations for metal overload (e.g., transfusion‑related iron overload, thalassemia, selected MDS cases) showing benefit on clinically relevant or surrogate outcomes.

See randomized trials and systematic reviews demonstrating benefit in iron‑overload states and selected low/intermediate‑risk MDS (TELESTO, systematic reviews).

Appropriate agent, route, and monitoring plan: The proposed chelating agent and route (oral or parenteral) are appropriate for the specific metal intoxication and include a monitoring plan for known risks (renal function, electrolytes, hematologic monitoring, liver tests, and other agent‑specific safety checks).

Agent, route, and monitoring should align with FDA labeling and recognized drug compendia and reflect the safety profiles described in clinical trials.

Unproven / Not medically necessary uses

Not medically necessary / Unproven:

Non‑overload chronic diseases: Chelation therapy to treat chronic, progressive non‑overload diseases (for example, cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, Parkinson disease, rheumatoid arthritis, chronic fatigue, multiple sclerosis, and other listed non‑overload conditions) is unproven and not medically necessary.

Systematic reviews and health technology assessments found studies to be small, methodologically limited, and inconsistent; guideline bodies do not support these uses.

Autism Spectrum Disorder: Chelation therapy for autism spectrum disorder is unproven and not medically necessary; randomized trials and a Cochrane review found no benefit and reported potential serious adverse events.

Risks include hypocalcemia, renal impairment, and death; evidence does not support efficacy.

Dental amalgam‑related mercury claims: Chelation to treat mercury 'toxicity' attributed to dental amalgam fillings is unproven and not medically necessary.

Amalgam fillings have not been shown to cause systemic harm except rare allergy; chelation for this purpose lacks supportive evidence.

Approved/Toxicologic Indications

Covered when ALL of the following are met:

Validated laboratory diagnosis or FDA‑approved indication: There is a validated laboratory diagnosis of metal intoxication or an FDA‑approved indication for the specific chelating agent (for example, lead poisoning or transfusional iron overload).

Specialty societies and toxicology authorities recommend chelation only for documented metal intoxication diagnosed with validated tests.

Clinical documentation linking diagnosis to treatment: Clinical documentation links laboratory findings to the clinical need for chelation and describes target goals for therapy (for example, reduction in serum ferritin, liver iron concentration, or clinical endpoints as appropriate).

Documentation should support the medical necessity and therapy objectives.

Monitoring and risk management plan: A monitoring and management plan is in place for known chelator risks (eg, renal monitoring, hematologic surveillance for deferiprone, liver tests) and for assessing therapeutic response.

Plan should reflect agent‑specific safety measures described in trials and product labeling.

Unproven / Not Medically Necessary Indications

Not covered / Not recommended for the following indications based on current evidence and guideline consensus:

Autism and neurodevelopmental disorders: Use of chelation for autism spectrum disorder or other neurodevelopmental disorders is not recommended due to lack of efficacy and potential for serious harm.

Cochrane review and regulatory warnings support non‑use; NICE recommends against chelation for autism.

Cardiovascular disease and stable ischemic heart disease: Chelation therapy for prevention or treatment of cardiovascular disease, stable ischemic heart disease, or to improve angina/exercise tolerance is not supported by current evidence and guideline statements; routine use is not recommended.

Multiple RCTs, Cochrane review, and major specialty guidelines (ACC/AHA/ACP/AHA, AHA, CCS) advise against chelation for CVD.

Neurodegenerative diseases and other investigational uses: Chelation for Parkinson disease, Alzheimer disease, or other neurodegenerative conditions is investigational; small trials are inconclusive and do not support routine use.

Available randomized trials are small and underpowered; further well‑designed studies are required.

Coverage rationale

Covered when aligned with FDA‑approved indications and recognized drug compendia:

FDA‑approved indications: Chelation agents are covered when used for FDA‑approved indications such as treatment of metal poisoning or iron overload and when use aligns with recognized drug compendia (eg, AHFS, DrugDex) and product labeling.as per FDA labeling and compendia

FDA approval and compendia references are informational and should guide appropriate use; FDA cautions against unsupported claims for autism and other non‑approved uses.

Off‑label/unsupported uses require compelling justification: Off‑label chelation uses (for example, to treat autism or to improve outcomes in stable ischemic heart disease) are not accepted indications in the absence of compelling evidence and guideline support.N/A

Major guideline bodies recommend against these uses and the FDA has issued warnings about improper marketing claims.

No high-quality, peer-reviewed evidence supports routine chelation therapy for a broad array of non‑overload conditions. Systematic reviews and health-technology assessments have repeatedly found that studies addressing chronic, progressive diseases (for example, cardiovascular disease, diabetes, cancer, Alzheimer’s disease, Parkinson’s disease) and many other listed conditions are small, methodologically flawed, heterogeneous in populations and regimens, lack adequate controls or blinding, and provide conflicting results. Given these limitations, chelation for non‑overload indications has not been shown to be safe and effective and is therefore considered unproven and not medically necessary.

Chelation has been evaluated for autism spectrum disorder (ASD), neurodevelopmental disorders, and cardiovascular disease, but current evidence does not support clinical benefit. A Cochrane review and randomized trial data found no improvement in ASD symptoms with pharmaceutical chelation and identified safety concerns. For cardiovascular disease, randomized trials and systematic reviews (including Cochrane analyses) report no consistent reduction in major cardiovascular events or reliable improvements in functional measures such as ankle‑brachial index or walking distance. These bodies of evidence underpin guideline and society positions that do not endorse chelation for these indications.

Major guideline groups and consensus statements recommend against chelation for autism or for improving angina or exercise tolerance in patients with stable ischemic heart disease. The American College of Physicians and related societies explicitly state that chelation should not be used to improve symptoms or reduce cardiovascular risk in stable ischemic heart disease, and the Canadian Cardiovascular Society issued a conditional recommendation against its use to improve angina or exercise tolerance. The American College of Medical Toxicology also warns that chelating agents are not indicated outside of documented metal intoxication and may cause serious adverse events.

Chelation therapy administered for non‑overload conditions, including attempts to treat alleged mercury 'toxicity' from dental amalgam fillings, is considered not medically necessary. The policy and supporting reviews find insufficient evidence that dental amalgams cause systemic harm warranting chelation, and the FDA has warned against improper promotional claims about chelators for conditions such as autism.

Use of chelation to treat ASD, cardiovascular disease, or neurodegenerative conditions is not supported by high-quality trials or by major specialty organizations. The Cochrane review and randomized studies for ASD found no benefit and identified potential for serious adverse events; systematic reviews and randomized trials in cardiovascular disease show no reliable reduction in major CVD outcomes. Professional bodies (ACMT, AAFP) and regulatory statements (FDA) conclude chelation should be reserved for documented metal intoxication and not used for these investigational indications.

Reiterating coverage stance: chelation therapy for conditions without documented heavy metal intoxication—such as autism, stable ischemic heart disease, and other non‑overload disorders—is not medically necessary. Requests for chelation in these contexts lack robust efficacy data, conflict with guideline recommendations, and may expose patients to significant harms; therefore coverage is not supported absent validated laboratory evidence of metal overload or other compelling, documented toxicologic indications.

Covered Regimens and Therapies

Agent / Regimen	Route	Key evidence / notes	Coverage status
Deferoxamine (DFO)	Parenteral (subcutaneous/infusion)	Used in transfusion‑related iron overload; lower adherence due to prolonged parenteral administration but effective in reducing ferritin and iron burden (reviewed by Lee et al.).	Covered
Deferiprone (DFP)	Oral	Shown noninferior to deferasirox in randomized trials for LIC and cardiac T2* (Kwiatkowski et al., Maggio et al.); acceptable safety profile though neutropenia/agranulocytosis reported.	Covered
Deferasirox (DFX)	Oral (tablets/granules)	Oral agent with convenience advantages; associated hepatic, gastrointestinal, and renal toxicities in some patients; used in comparative noninferiority trials versus DFP.	Covered
Combination: Deferiprone + Deferasirox (DFP + DFX)	Oral combination regimens	Small single‑arm and comparative studies report reductions in serum ferritin and LIC, improved cardiac T2* in severe overload, and generally tolerable safety and good adherence in most studies (Salem et al. review).	Covered
Comparative trial findings	—	Randomized noninferiority trials (Maggio et al., Kwiatkowski et al.) demonstrate DFP noninferior to DFX for primary efficacy endpoints (serum ferritin, LIC, cardiac T2*); adverse event profiles differ by agent.	Neutral (informational)

Line of therapy informational criteria

ICT in low/intermediate‑risk MDS (informational): Iron chelation therapy may be considered in low‑ and intermediate‑risk myelodysplastic syndrome (MDS) with iron overload; randomized trial (TELESTO) showed prolonged event‑free survival with deferasirox versus placebo in low/intermediate‑1 risk patients.

This node is informational regarding line of therapy and does not mandate sequencing of chelators.

Coding

Referenced procedure/drug HCPCS/J codes and infusion codesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Provider Actions and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for chelating agents and infusion services when used for covered indications. Requests for EDTA/edetate disodium infusions or other chelation administrations should include supporting documentation of metal overload/intoxication and will be reviewed against policy criteria.

Prior authorization required for infusion-administered chelators (e.g., EDTA/edetate disodium) and for facility/home infusion per diem billing (S9355).
Include J‑codes and HCPCS codes on authorization requests to expedite review (see Applicable Codes).

Prior Authorization

EDTA/Chelation for Cardiovascular Indications — Prior Authorization Recommended

For EDTA/chelation infusions requested for cardiovascular indications (e.g., atherosclerotic CVD, post‑MI care), prior authorization is recommended and denials may occur because randomized trials and systematic reviews show mixed or no benefit for CVD outcomes.

Requests for EDTA chelation to treat or prevent cardiovascular disease should include compelling, diagnosis‑specific rationale and documentation of metal overload if claimed.

Background

Chelation therapy works by administering agents that bind specific metals and facilitate their excretion. When used for documented heavy‑metal overload (for example, iron, lead, copper, aluminum), appropriate chelators and routes of administration are selected based on the metal involved, the severity of overload, and established toxicologic indications. Randomized trials, observational studies, and recognized clinical guidance support chelation for validated cases of metal intoxication or transfusional iron overload, where monitoring and management of known chelation risks (renal function, electrolytes, essential mineral depletion) are performed as part of care.

Definitions

Chelation therapy

DefinitionAdministration of molecules that bind and enable excretion of specific metal toxins; the medication, route, method, and site of administration vary depending on the chelating agent, toxicity level, and clinical indication.

PurposeFacilitates removal of heavy metals (e.g., iron, copper, lead, aluminum, mercury) from the body by forming complexes that are excreted.

Clinical useEstablished treatment for documented heavy metal overload (e.g., transfusional iron overload, lead poisoning) when diagnostic workup and reference values confirm toxicity.

Administration considerationsAgent selection and route (oral vs parenteral/infusion) depend on the specific metal, severity of overload, and agent safety profile.

Non‑overload conditions

Definition

Revision History

2025-08-01title_updateLatest

Policy title changed from 'Chelation Therapy for Non-Overload Conditions (for New Mexico Only)' to 'Chelation Therapy (for New Mexico Only)'.

2025-08-01material_policy_revision

Policy language clarified to state chelation for heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum) is proven and medically necessary (material change).

2025-08-01supporting_information_update

Clinical Evidence and References sections were updated and the previous policy version CS016NM.A was archived.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy (for New Mexico Only)

Policy CodePolicy CS016NM.B

Change TypeTitle and clinical clarification (material)

Effective DateAug 1, 2025

Next Review DateN/A

Key ActionObtain and include validated laboratory testing demonstrating metal intoxication (e.g., blood lead level) in documentation to support authorization for chelation.

SourceLink

On This Page

Justification for chosen agent and route: The selected chelating agent and route (oral versus infusion/parenteral) are justified based on the metal involved, severity of overload, prior therapies, adherence considerations, and safety profile.

Comparative trials (eg, DFP vs DFX) and combination regimens inform agent selection and expected outcomes.

Dental amalgam‑related mercury: Chelation to treat alleged systemic harm from dental amalgam mercury is not recommended; evidence does not show adverse systemic health effects from amalgam in most people.

FDA guidance and reviews do not support chelation for dental amalgam exposure except in rare allergy or specified intoxication scenarios.

Other investigational or unsupported indications: Other proposed indications lacking quality evidence (eg, rheumatoid arthritis, chronic fatigue, osteoporosis, vision disorders, etc.) are not covered.

Hayes health technology assessment and policy review found studies to be small, heterogeneous, and methodologically limited.

Be aware: routine use of chelation for CVD (including attempts to treat ASCVD, improve cardiac outcomes, or as alternative therapy) is not supported by high‑quality evidence and is at high risk for denial.

Prior Authorization

Authorization Guidance and Policy Expectations

Policy revision clarifies prior‑authorization expectations: chelation is covered only for documented metal overload/intoxication and must align with FDA‑approved indications or authoritative drug compendia. Non‑approved uses are subject to denial.

Authorization reviewers will require documentation of indication consistent with FDA‑approved uses and compendia (e.g., lead poisoning, iron overload).
Requests for chelation for non‑overload conditions will be evaluated against policy criteria and may be denied.
Ensure billing and prior‑auth submissions reference the applicable policy number CS016NM.B and effective date.

Step Therapy

No step‑therapy protocol is specified in this policy. Clinical evidence discusses multiple chelators and combination regimens (e.g., deferiprone, deferasirox, deferoxamine) but does not mandate a required sequencing of agents.

When multiple chelators are clinically reasonable (monotherapy or combination), document prior treatment history, contraindications, and rationale for the chosen agent.
If an insurer or benefit plan implements a separate step‑therapy requirement, follow that plan's specific rules — this policy does not define a step‑therapy cascade.

Documentation Required

Required Diagnostic Documentation

Submit diagnostic documentation demonstrating validated laboratory testing that confirms metal intoxication or overload. Documentation should include test type, specimen source, numeric results with reference ranges, and relevant clinical history.

Acceptable evidence includes validated serum, whole blood, urine, or organ‑specific testing with reference values and interpretation.
Provide clinical history consistent with exposure/overload (e.g., transfusion history for iron overload, environmental/occupational exposure for lead).
If chelation is requested as a treatment trial without objective evidence of overload, include rationale and prior diagnostic attempts.

Documentation Required

Documentation Required for Approved Indications

For approved indications, include documentation of validated laboratory confirmation of metal intoxication (e.g., elevated serum ferritin, elevated blood lead levels, hepatic iron concentration) and any relevant imaging or specialty consultations.

Laboratory values should be linked to diagnostic criteria used to support chelation (e.g., transfusion‑related iron overload with elevated LIC or ferritin).
Attach prior specialty notes (e.g., hematology, medical toxicology) when available to support necessity.

Denial Risk

High Denial Risk — Non‑Overload Indications

Requests to use chelation therapy for chronic, progressive non‑overload conditions or to treat mercury from dental amalgam fillings are considered unsupported by evidence and are high risk for denial.

Examples of likely denial triggers: treatment for CVD without documented metal overload, autism, Alzheimer's disease, Parkinson's disease, and dental amalgam‑related mercury claims.
If submitted for these indications, include robust justification and objective metal‑overload testing; absent that, expect denial.

Documentation Required

Use of FDA‑Approved Chelators — Alignment with Approved Indications

FDA‑approved chelating agents must be used in accordance with their FDA‑approved indications and as referenced in recognized drug compendia. Off‑label uses lacking objective evidence are subject to denial and may prompt billing scrutiny.

Ensure drug selection, dosing, route, and indication align with FDA labeling or compendia entries.
Beware of marketing claims for autism or other non‑approved uses; these uses are not FDA‑supported and carry substantial denial and safety risk.

Billing Rule

Billing and Coding Caution

When billing for chelation infusions or home infusion services, include appropriate J‑codes and HCPCS to avoid payment confusion. Coding that implies treatment for unsupported indications (e.g., autism, CVD without overload) may trigger claim denials or audits.

Common codes: J0600 (edetate calcium disodium), J0470 (dimercaprol), J0895 (deferoxamine), J3520 (edetate disodium), HCPCS M0300 (IV chelation therapy), S9355 (home infusion per diem).
Bill drugs separately from infusion per diem; include clinical documentation with claims to support medical necessity.

Note

Provider Action Highlight

Provider actions to expedite review: verify documented metal overload with validated tests, include prior specialty consultations, supply complete medication and dosing history, and reference policy CS016NM.B and effective date on requests.

Confirm and attach objective laboratory or imaging evidence of intoxication.
Document prior treatments, contraindications, and rationale for chosen chelator.
Reference policy number CS016NM.B and effective date (2025‑08‑01) on all prior authorization submissions.

Conditions in which acute or chronic heavy metal toxicity has not been demonstrated and removal of metals is hypothesized to provide clinical benefit.

ExamplesProposed uses include cardiovascular disease, rheumatoid arthritis, cancer, diabetes, neurodegenerative disorders, and other chronic progressive diseases.

Evidence summaryCurrent evidence is insufficient to support efficacy for non‑overload conditions; such uses are considered unproven and not medically necessary.

Policy implicationRequests for chelation for non‑overload conditions (including mercury from dental amalgam) are subject to denial absent documented metal intoxication.

EDTA (EDTA-based chelation)

TermEDTA (ethylene diamine tetra‑acetic acid)‑based chelation

Use describedParenteral EDTA‑based infusions were evaluated in randomized trials for cardiovascular indications (e.g., post‑MI patients); trials showed no consistent reduction in major cardiovascular events.

Authorization guidancePrior authorization is recommended for therapeutic EDTA or other chelation infusions and should confirm documented metal intoxication or compelling clinical rationale.

DMSA

AgentDMSA (dimercaptosuccinic acid)

Formulation/routeOral agent used in clinical studies (e.g., trials in children with ASD evaluated oral DMSA cycles).

Evidence and safetyRandomized trial data do not show benefit for ASD and reported serious adverse events (e.g., hypocalcemia, renal impairment) indicate risks outweigh unproven benefits.

Iron chelators

Agents referencedDeferasirox (oral) and deferiprone (DFP; oral)

IndicationsUsed primarily for treatment of transfusional iron overload and studied in iron‑overload conditions such as thalassemia and MDS; combination regimens (DFP + DFX) have been evaluated in small studies.

Evidence noteRandomized and observational studies support efficacy in reducing ferritin and organ iron; agent choice depends on clinical context and monitoring needs.

FDA‑approved chelating agents

DefinitionChelating agents that have FDA approval for specific indications such as treatment of metal poisoning or iron overload.

Coverage considerationUse should align with FDA‑approved indications and generally recognized drug compendia (e.g., AHFS, DrugDex); FDA approval alone is informational and not sole basis for coverage decisions.

ExamplesFDA‑approved chelators include agents used for lead poisoning and transfusional iron overload (agent‑specific labeling determines approved uses and monitoring).